Vermeulen, S.; Awada, G.; Keyaerts, M.; Neyns, B.; Everaert, H.
Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Curr. Oncol. 2021, 28, 1630-1640.
https://doi.org/10.3390/curroncol28030152
AMA Style
Vermeulen S, Awada G, Keyaerts M, Neyns B, Everaert H.
Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Current Oncology. 2021; 28(3):1630-1640.
https://doi.org/10.3390/curroncol28030152
Chicago/Turabian Style
Vermeulen, Sim, Gil Awada, Marleen Keyaerts, Bart Neyns, and Hendrik Everaert.
2021. "Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome" Current Oncology 28, no. 3: 1630-1640.
https://doi.org/10.3390/curroncol28030152
APA Style
Vermeulen, S., Awada, G., Keyaerts, M., Neyns, B., & Everaert, H.
(2021). Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Current Oncology, 28(3), 1630-1640.
https://doi.org/10.3390/curroncol28030152